In addition, KRASG12D mutations have been found to be often associated with unfavorable overall survival outcomes in a significant proportion of cancer patients and exhibit resistance to anti-EGFR and anti-PD-1 therapy138-140. This evidence concerns the gene EGFR and cancer.